Medicare drug spending is rising faster than anticipated, largely due to the surging utilization of GLP-1 medications. This trend is occurring alongside the financial impacts of the Democrats' redesign of Part D drug coverage. The increased cost burden highlights the growing influence of peptide-based weight loss drugs on federal healthcare budgets.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.